The Thesis
PanicFade v4 is a contrarian mean-reversion strategy built on a simple, well-documented behavioural premise: markets overreact to negative headlines, and prices tend to revert toward fundamentals once the panic exhausts itself. Concretely, it buys names where sentiment drops below -0.4 and the stock is already technically oversold (RSI14 under 35, trading below its SMA20), then sizes into the weakness. Exits are equally rule-bound — it takes profits on reversion (RSI14 back above 50, or price reclaiming the SMA20) and hard-stops fresh lows on continued negativity, treating that as a genuine fundamental break rather than noise.
The design draws on 2025 sentiment-asymmetry research (arXiv:2509.11970) and the broader negative-media overreaction literature. It operates in a tight universe of 24 blue-chip large caps — Apple, Microsoft, JPMorgan, Walmart, and peers — which keeps liquidity high and idiosyncratic blow-up risk low.
Validation: The Strong Part
This is where PanicFade v4 earns its keep. The four-fold walk-forward test passed, and all four folds were positive — no single lucky window carrying the result. The out-of-sample stretch (May 2025–Aug 2026) returned 21.7% at a 2.44 Sharpe with only a 2.6% drawdown, the strongest fold by a wide margin. A Probabilistic Sharpe Ratio of 0.985 across 27 trials is genuinely reassuring: even after accounting for selection effort, the edge is unlikely to be pure noise. The Deflated Sharpe Ratio of 0.56 is more sobering but still positive — the strategy survives the deflation, if not triumphantly.
Performance and the Costs
The full backtest returned 37.93% over 1,233 trading days, ending at $13,793 from a $10k base. That headline masks a modest 6.79% CAGR and a Sharpe of 0.96 — respectable, not spectacular. The win rate of 62.88% across 530 trades is healthy, and max drawdown of 9.3% is admirably contained for an equity strategy.
The glaring risk is turnover: 5,807%. That is a strategy churning its capital nearly 60 times over, and it paid $530 in fees to do it — a real, structural drag that eats directly into an already-modest CAGR. Any degradation in fill quality or fee assumptions would hit this strategy harder than most.
Live Activity
Recent live behaviour reflects the strategy's patience — perhaps too much. Across six scheduled runs from September 9–16, only one trade executed: 21 shares of BAC at $59.86 on the 15th, following a WMT buy on August 28. Most days close with zero executions, which is by design — panic setups are rare. But the live paper account sits at roughly $9,991, marginally below its $10k start, so the promising validation numbers have yet to translate into live gains.
Verdict
PanicFade v4 is one of the more intellectually honest strategies in the stable: a coherent thesis, a validation regime that actively tries to disprove itself, and disciplined risk controls. The reservations are turnover-driven cost drag, a sub-1.0 headline Sharpe, and a live track record still waiting to prove the backtest. Watch the fees, and watch whether the OOS strength holds when real capital, not just paper, is on the line.